Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-76,page-paged-76,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

CLIENT NEWS

 

 

  • Expedeon AG licenses Lightning-Link® Rapid Biotinylation technology to Cell Guidance Systems in supply agreement
    08 January 2019
    www.expedeon.com
  • Sterna biologicals prepares for phase IIb clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis
    08 January 2019
    www.sterna-biologicals.com
  • AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies
    08 January 2019
    www.ayoxxa.com
  • Molecular Health licenses its proprietary predictive analytics to DATEN CAPITAL
    07 January 2019
    www.molecularhealth.com
  • Biom’up: Achievement of two major development milestones
    07 January 2019
    www.biomup.com
  • Rentschler Biopharma completes acquisition of U.S. manufacturing site
    03 January 2019
    www.rentschler-biopharma.com
  • InflaRx continues U.S. expansion with addition of New York City corporate office and addition of management
    03 January 2019
    www.inflarx.com
  • Verona Pharma appoints Kathleen Rickard, MD, as chief medical officer to lead late stage clinical development of RPL554
    03 January 2019
    www.veronapharma.com
  • Atriva Therapeutics announces first closing of series A financing round
    03 January 2019
    www.atriva-therapeutics.com